Humacyte falls after US FDA extends review of co's blood vessel implant

Humacyte

12/08/2024 09:38

** Shares of biotech firm Humacyte  HUMA.O  slide 12.1% to
$6.9 in premarket 
    ** Co on Friday said U.S. Food and Drug Administration (FDA)
extended review of its blood vessel implant
    ** Implant, called Human Acellular Vessel (HAV), used to
treat patients with injured blood vessels
    ** Regulator asked for additional time to complete review,
without disclosing a new decision date
    ** FDA was expected to announce decision on Aug. 10 
    ** Brokerages rate stock "buy" or higher on avg; median PT
is $10.50 - LSEG data
    ** HUMA up 178.52% this yr vs 11.55% increase in Nasdaq
index  .IXIC 

 (Reporting by Nikhil Sharma in Bengaluru)
 ((Nikhil.Sharma@thomsonreuters.com;))